EDWARD BARIAS: Open Payments
NPI 1689007700 · JUPITER, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,968 in 172 payments from 20 companies in 2025. Trend: 2023 $3,011 · 2024 $4,487 · 2025 $3,968
Food & beverage: $3,968
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 16 | $651 |
| ABBVIE INC. | 34 | $495 |
| Otsuka America Pharmaceutical, Inc. | 10 | $406 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $387 |
| Axsome Therapeutics, Inc. | 12 | $357 |
| Alkermes, Inc. | 16 | $340 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $193 |
| E.R. Squibb & Sons, L.L.C. | 11 | $165 |
| Vanda Pharmaceuticals Inc. | 9 | $162 |
| Janssen Pharmaceuticals, Inc | 6 | $140 |
Products named: INGREZZA, VRAYLAR, REXULTI, CAPLYTA, Auvelity, ARISTADA, TRINTELLIX, COBENFY.
Industry payments across FL — which companies pay providers there.
